Chengappa K N, Levine J, Ulrich R, Parepally H, Brar J S, Atzert R, Brienzo R, Gopalani A
University of Pittsburgh, Western Psychiatric Institute & Clinic, Special Studies Center @ Mayview State Hospital, 3811 O'Hara Street, Pittsburgh, PA 15213-2593, USA.
Can J Psychiatry. 2000 Nov;45(9):827-32. doi: 10.1177/070674370004500907.
To evaluate the impact of risperidone on seclusion and restraint in patients at a state psychiatric facility, shortly after risperidone's release.
Patients who were in the hospital for at least 3 months prior to receiving risperidone and subsequently received risperidone for at least 3 months formed the cohort. A mirror-image design was used with duration to a maximum of 1 year before and 1 year after initiation of risperidone. The hospital population that did not receive either risperidone or clozapine during the same time period was used for comparison of trends of seclusion and restraint.
Seventy-four patients (most with schizophrenia) met the inclusion criteria of the risperidone group. There were statistically significant decreases in the number of seclusion hours (2.2 [SD 5.5] to 0.26 [SD 0.06]) and of events (0.23 [SD 0.59] to 0.05 [SD 0.14]) per person per month during risperidone treatment, compared with the prerisperidone treatment period (P = 0.01). The comparison group also evidenced decreases on these measures during the same time period, but the risperidone-treated cohort achieved a proportionally greater reduction. There were similar trends toward reduction in the restraint measures during risperidone treatment compared with prerisperidone, but these did not achieve statistical significance. The comparison group also showed slightly decreased use of restraints over the study period.
Risperidone appears to have had a positive impact on seclusion in this state-hospital psychiatric population. These data support the positive impact of risperidone on violence found in other studies. Violence and aggression are major factors that affect morale among psychiatric patients and staff. So, any benefit in this regard as a result of antipsychotic drug treatment is salutary for patients, families, and health care providers.
评估利培酮在上市后不久对一家州立精神病机构患者隔离和约束措施的影响。
在接受利培酮治疗前已住院至少3个月且随后接受利培酮治疗至少3个月的患者组成队列。采用镜像设计,利培酮治疗开始前和开始后各有最长1年的时间段。将同期未接受利培酮或氯氮平治疗的医院患者群体用于比较隔离和约束措施的趋势。
74名患者(大多数为精神分裂症患者)符合利培酮组的纳入标准。与利培酮治疗前相比,利培酮治疗期间每人每月的隔离小时数(从2.2[标准差5.5]降至0.26[标准差0.06])和隔离事件数(从0.23[标准差0.59]降至0.05[标准差0.14])有统计学显著下降(P = 0.01)。同期对照组在这些指标上也有下降,但接受利培酮治疗的队列下降幅度更大。与利培酮治疗前相比,利培酮治疗期间约束措施也有类似的下降趋势,但未达到统计学显著水平。对照组在研究期间约束措施的使用也略有下降。
利培酮似乎对该州立医院精神科患者的隔离措施产生了积极影响。这些数据支持了其他研究中利培酮对暴力行为的积极影响。暴力和攻击行为是影响精神科患者及工作人员士气的主要因素。因此,抗精神病药物治疗在这方面的任何益处对患者、家属和医疗服务提供者都是有益的。